Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis.
about
Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosisImmunity, atherosclerosis and cardiovascular diseaseCD8+ T cells mediate the athero-protective effect of immunization with an ApoB-100 peptideModel IgG monoclonal autoantibody-anti-idiotype pair for dissecting the humoral immune response to oxidized low density lipoproteinB cells and humoral immunity in atherosclerosisInflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics.The inhibitory FcγRIIb modulates the inflammatory response and influences atherosclerosis in male apoE(-/-) miceImmunization of Chlamydia pneumoniae (Cpn)-infected Apob(tm2Sgy)Ldlr(tm1Her)/J mice with a combined peptide of Cpn significantly reduces atherosclerotic lesion development.Induction of T helper 2 responses against human apolipoprotein B100 does not affect atherosclerosis in ApoE-/- mice.Circulating autoantibodies against the apolipoprotein B-100 peptides p45 and p210 in relation to the occurrence of carotid plaques in 64-year-old women.Modulation of recombinant antigenic constructs containing multi-epitopes towards effective reduction of atherosclerotic lesion in B6;129S-Ldlr(tm1Her)Apob(tm2Sgy)/J miceVaccination to modulate atherosclerosisPathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for interventionInflammatory Ly-6C(hi) monocytes play an important role in the development of severe transplant arteriosclerosis in hyperlipidemic recipientsImmune response to lipoproteins in atherosclerosis.Vaccination against T-cell epitopes of native ApoB100 reduces vascular inflammation and disease in a humanized mouse model of atherosclerosis.Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy a reality?Immunomodulation of atherosclerosis with a vaccine.Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesionsImmunoglobulins against tyrosine-nitrated epitopes in coronary artery diseaseDistinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia.Autoimmunity in atherosclerosis: a protective response losing control?2015 Russell Ross Memorial Lecture in Vascular Biology: Protective Autoimmunity in AtherosclerosisTargeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques.Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice.Imbalance between endothelial damage and repair: a gateway to cardiovascular disease in systemic lupus erythematosus.Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseasesProgress and future opportunities in the development of vaccines against atherosclerosis.Control of dichotomic innate and adaptive immune responses by artery tertiary lymphoid organs in atherosclerosis.Vaccines against atherosclerosis.Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges.Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis.Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential.Cloning and expression of an anti-LDL(-) single-chain variable fragment, and its inhibitory effect on experimental atherosclerosis.The immunology of atherosclerosis.Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression.A vaccine against atherosclerosis: myth or reality?Tim-1+ B cells suppress T cell interferon-gamma production and promote Foxp3 expression, but have impaired regulatory function in coronary artery disease.Antibodies against electronegative LDL inhibit atherosclerosis in LDLr-/- mice.Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells.
P2860
Q26822962-8F7BC2E2-17AA-41FF-A394-D58B701B43B2Q28688590-69A15C19-0164-41B4-939A-742CA7C83F0BQ28732168-ED608589-60FB-42FB-9DA9-1D30D4A75E9BQ31055400-AD8CB6A4-4EE3-4EBD-87ED-69E01B2CB244Q33789638-99F225E4-409C-4F0F-A453-B014484F968FQ33805176-6A8DE9CD-6616-4BFF-9EB2-149328D3EA48Q34644753-A4ED8F67-2F41-482C-8F0C-555A0DC8D5C7Q35069480-4A2E64E9-E7B5-441B-B659-1A4FA3C5829CQ35174901-5A71A6B7-274E-4AB0-951D-209003F27A70Q35175305-815D61C8-6DEF-45F5-BE76-361EC1719398Q35591762-C01B618C-E37B-4D80-A138-242FC948601DQ35600876-0545D17E-1071-441C-9FF8-1F03E582ADB3Q35998510-445163D1-0CB2-4545-A3CC-831089AD7814Q36177467-FF090021-CE67-4E62-B093-5D521CAB0776Q36203882-5D4AD833-85C0-419F-83A7-871161DDDE1BQ36279562-BB51AF84-0A05-40E9-8871-5CE87D188B0EQ36283424-56C951BB-CEB2-4200-AADA-37FF609EF8F2Q36321769-76A4900E-B692-41D8-96B5-D272DA96C43BQ36387263-6E044FF5-DC8E-4CAC-A977-E04F57D18C01Q36411136-5836770D-CBA5-4A36-AC1C-E4A1F8DD3F77Q36713445-8BA52142-BF44-4E04-9A36-408847E3AC05Q37138017-536F2BFE-80FF-4456-97E9-4AA5D4AC2C84Q37146276-266796F0-F8D9-4F65-949D-761F4943BDC2Q37173369-F6F57050-E332-464A-85BB-86D843194BBAQ37385727-A05AA57B-7B11-424F-9223-3FEB3ED1FC26Q37699812-190FFF7E-A2EB-4316-A577-0B6460B9B179Q37709623-8E8083A1-C822-44E0-AEB7-CD00EB9C1155Q37835406-B8CFF73F-F2B1-4CD1-A14F-3B1D8B02F04AQ38025388-0E8C2FFC-B72D-4DD8-9B45-86C6E66B38B9Q38089941-C3BF07A4-9AE1-4E90-821D-EB3BA26E9278Q38346930-EE634857-3997-4B60-9721-7676882EF41EQ38406177-2747075F-19F9-47EF-9989-570E8751AE7DQ38620803-FF7C2006-442B-4499-AA11-00A7BEC566C7Q39113883-6021E431-D5FC-4209-A3B9-69E81E5C4002Q39230390-28319572-EC2E-4476-8525-C92482431525Q39601696-7F086969-071A-4F3C-8E83-5FD4AD1085D5Q40119196-A665B509-6DBD-462D-94EF-2806FB0192E7Q41954207-82D96B3D-8829-4906-9A0D-6AD71F8E6EBCQ46160486-CAA77ECF-97F3-425D-B66D-B65D172960D0Q46473311-4D3E1EB8-CAA3-4EE4-8A8C-F7F7195B1CAD
P2860
Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Recombinant human antibodies a ...... ences inhibit atherosclerosis.
@ast
Recombinant human antibodies a ...... ences inhibit atherosclerosis.
@en
type
label
Recombinant human antibodies a ...... ences inhibit atherosclerosis.
@ast
Recombinant human antibodies a ...... ences inhibit atherosclerosis.
@en
prefLabel
Recombinant human antibodies a ...... ences inhibit atherosclerosis.
@ast
Recombinant human antibodies a ...... ences inhibit atherosclerosis.
@en
P2093
P1433
P1476
Recombinant human antibodies a ...... ences inhibit atherosclerosis.
@en
P2093
Alexandru Schiopu
Gunilla Nordin Fredrikson
Ingrid Söderberg
Jan Nilsson
Jenny Bengtsson
Mikko P S Ares
Prediman K Shah
Roland Carlsson
Stefan Lindgren
P304
P356
10.1161/01.CIR.0000143162.56057.B5
P407
P577
2004-09-27T00:00:00Z